Skip to main content
. Author manuscript; available in PMC: 2015 Oct 28.
Published in final edited form as: Cancer Lett. 2014 Jul 24;353(2):281–289. doi: 10.1016/j.canlet.2014.07.032

Figure 5. Anti-angiogenic activity of FAK inhibitor C10.

Figure 5

(A) HUVEC cells were plated on basement membrane extract coated wells and treated with DMSO (control) or C10 at the indicated concentrations. Capillary tube formation was then assessed at 6 h and 24 h and the number of loops were analyzed from 7–10 fields for each condition. Representative images from three independent experiments are shown. Error bars represent mean ± S.D. *p <0.05. (B) Transwell plates were used to determine HUVEC cell motility following DMSO (control) or C10 treatment at the indicated concentrations for 24 h. FGF2 was included as a positive control. Migrated cells were stained followed by dye extraction and the absorbance (590 nm) was measured for each condition. Data are presented as mean ± S.D. of three experiments. *p <0.05. (C) The effect of C10 on in vivo angiogenesis was evaluated using the directed in vivo angiogenesis assay (DIVAA). Angioreactors (n=4) were prepared and implanted as described in the Materials and methods. Avastin was included as a negative control. The extent of endothelial cell invasion in the angioreactors for each condition was determined by fluorescence quantitation of FITC-Lectin and is reported as relative fluorescent units (R.F.U). Results are shown as mean ± S.D. *p <0.05.